Your session is about to expire
← Back to Search
Methadone for Laminectomy
Study Summary
This trial is testing whether ketamine and methadone can reduce pain after lumbar surgery.
- Laminectomy
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are applicants below the age of 65 permissible to partake in this inquiry?
"As per the trial requirements, participants must be aged 18-80 to qualify for inclusion."
What is the current size of the cohort involved in this investigation?
"All recruitment for this clinical trial has been concluded. Initially launched in February 1, 2013 and edited on the 9th of the same month this year, it is no longer accepting participants. Alternately, there are currently 484 trials actively admitting candidates undergoing laminectomy and 113 studies that use Methadone recruiting new patients."
Has Methadone been granted official sanctioning by the FDA?
"As this phase 4 clinical trial suggests, Methadone is approved for use and thus earned a safety rating of 3."
Are individuals currently being accepted to participate in this experiment?
"According to records on clinicaltrials.gov, this trial has not been actively seeking out participants since February 9th 2022; the original post date was 2/1/13. Nonetheless, there are still 597 other trials that are currently recruiting patients."
Is there an opportunity to participate in this research?
"This study is accepting a cohort of 114 adult volunteers, aged between 18 and 80, that require laminectomy. To be eligible for admission to the trial, participants must meet these requirements: • Be over 18 years old but under 80• Possessing either gender identity• Requiring elective lumbar laminectomy"
Is this an unprecedented exploration of the subject?
"As of now, 113 Methadone studies are running in 83 cities and 22 countries. The initial trial for this drug took place in 2011; sponsored by Laboratoires Bouchara-Recordati, it had 146 participants and finished its Phase 3 trials successfully. Since then, 531 separate experiments have been conducted."
Share this study with friends
Copy Link
Messenger